Abbott Wins Approval for CATALYST Trial for At-Risk Stroke Patients

Abbott Wins Approval for CATALYST Trial for At-Risk Stroke Patients

Source: 
Medical Devices and Diagnostics Industry
snippet: 

Lately, it seems as if Abbott Laboratories has been extremely busy building its structural heart offerings. The most recent example of this is the company winning FDA approval to conduct a new trial designed to assess the Amplatzer Amulet Left Atrial Appendage (LAA) Occluder for people with atrial fibrillation (AFib).